Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Recent Articles
RELATED ARTICLES
-
Innovent ditches low-value stake sale after investor outcry
1801.HK - Innogen Pharma jostles for a slice of the weight-loss market
- Cancer drug maker Genfleet joins Hong Kong IPO influx
- PegBio aims to bulk up its finances to deliver weight-loss drugs
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
